Skip to main content
Search
Main content
Analytical chemistry
Published

Profiling Protein Aggregate Size Using Single-Molecule Array Technology

Authors

Dorothea Böken, Yunzhao Wu, Jianli Zhang, Zengjie Xia, Paula Beltran-Lobo, Cara L Croft, Savinu Weerasekera, Amanda Heslegrave, Henrik Zetterberg, Ashvini Keshavan, Jonathan M Schott, Maria Jimenez-Sanchez, David C Duffy, David Klenerman

Abstract

Anal Chem. 2026 Jun 25. doi: 10.1021/acs.analchem.6c03315. Online ahead of print.

ABSTRACT

Protein aggregation is a central feature of many neurodegenerative diseases, yet methods to characterize aggregate size in complex biological samples remain limited. Here, we show that fluorescence intensity from individual single-molecule array (Simoa) microwells encodes size-dependent information beyond conventional digital quantification. Using defined synthetic tau assemblies, we establish that increasing aggregate size produces higher microwell brightness. Applying this technique to human brain homogenate reveals a shift toward larger tau aggregates in Alzheimer's disease compared to age-matched controls, in agreement with orthogonal measurements by single-molecule super-resolution microscopy. Brightness profiling further captures time-dependent aggregate size increase in a neuronal cell model, demonstrating sensitivity to dynamic changes in aggregation. Although resolution is limited between similarly sized small species, Simoa brightness robustly reports population-level shifts in aggregate size distributions. These findings repurpose a widely used ultrasensitive detection platform to provide high-throughput structural as well as quantitative insight into protein aggregation in biological systems.

PMID:42348734 | DOI:10.1021/acs.analchem.6c03315

UK DRI Authors

Dr Amanda Heslegrave

Principal Research Fellow

Co-leading the UK DRI Biomarker Factory platform based at UK DRI at UCL

Dr Amanda Heslegrave

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg

Prof David Klenerman

Group Leader

Determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies

Prof David Klenerman